Virbac : Disposal of Sentinel® (parasiticides / US) – Estimates and target price adjusted
>Sale of Sentinel rights to MSD (Merck & Co.) for $ 400m - Virbac announced yesterday that it has sold its veterinary products currently marketed under the Sentinel® brand in the US (internal anti-parasitic) for $ 400m. The deal is submitted to the FTC, but we understand that Virbac is expecting a closing by mid-20. MSD justifies this transaction by the complementarity of Sentinel with certain other of its products (such as Bravecto®). Virbac estimates that the financ...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.